TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03307252
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablet
Study: NCT01357837
Drug: GRT6005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
Study: NCT00648882
Drug: LEVOTHYROXINE SODIUM TABLETS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x300mcg, single dose fasting
Study: NCT00648882
Drug: SYNTHROID® 300 mcg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x300mcg, single dose fasting
Study: NCT04823065
Drug: hyoscine-n-butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 20 mg Buscopan, intravenous
Study: NCT04573322
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
Study: NCT00970346
Drug: OligoG CF-5/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
Study: NCT03631706
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
Study: NCT03858751
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule before bedtime
Study: NCT03858751
Drug: LTM1201AZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTM1201AZ oral capsule before sleep
Study: NCT03858751
Drug: LTM1201AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTM1201AT oral capsule before sleep
Study: NCT03858751
Drug: LTM1201AD
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTM1201AD oral capsule before sleep
Study: NCT01195311
Drug: INCB024360
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.
Study: NCT00107861
Drug: Ad.hIFN-β (BG00001, IDEC-201)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01825473
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01825473
Drug: Placebo (D5W)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03067727
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The DVI contains 10 mg Dinoprostone
Study: NCT03067727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo product is identical with the active product except that it does not contain Dinoprostone.
Study: NCT02345980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00856492
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00856492
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03692286
Drug: Calcium Hydroxide Intracanal medication
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide intracanal medication
Study: NCT03312244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02374736
Drug: Privigen (Human normal immunoglobulin G (IgG > 98 % purity))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL.
Study: NCT04332094
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg / day v.o. for 3 days
Study: NCT04200651
Drug: Prednisolone Acetate 1% Oph Susp
Normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
Study: NCT01769573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo to be used will be Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin. Placebo will be supplied in 2 ml borosilicate glass vials sealed with butyl stoppers containing 0.5 ml.
Study: NCT01950468
Drug: NAV5001
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous dose of 8.0 ± 1.0 mCi
Study: NCT03441412
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated.
Study: NCT03292666
Drug: Oral Anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants used to treat or prevent venous thromboembolism
Study: NCT02563054
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
Study: NCT04527133
Drug: Aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous or inhalation
Study: NCT03144661
Drug: INCB062079
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
Study: NCT02153177
Drug: Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
Study: NCT02513160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices.~The placebo devices were identical to the devices used to deliver active drug.
Study: NCT04574713
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 over-encapsulated tablet once daily, containing placebo, for 12 weeks (84 days).
Study: NCT02729025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously once a month using an autoinjector/pen.
Study: NCT00295581
Drug: PpPfs25/ISA51 & ScPvs25/ISA51
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00533481
Drug: MK0557
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01415518
Drug: theophylline SR
Normalized name: Theophylline SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
Study: NCT00240448
Drug: valsartan 160 mg/hydrochlorothiazide 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00240448
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02416063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:Caudal bupivacaine 0.25% 1ml/kg~Intravenous: Normal saline 10 ml~sevoflurane Induction and maintenance of anesthesia
Study: NCT00632268
Drug: RAD001; Cisplatin; 5-FU; Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
Study: NCT00663936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT02253511
Drug: Cidan capsule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03334240
Drug: CLS003
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLS003
Study: NCT03334240
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT00324818
Drug: metronidazole and azithromycin
Normalized name: metronidazole and diloxanide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03456102
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.
Study: NCT02453932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
Study: NCT01037842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo three times a day added to metformin 500 mg three times a day for 16 weeks
Study: NCT01697072
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is an oral fluoropyrimidine.
Study: NCT00513695
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00513695
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03861390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
Study: NCT01907490
Drug: Ha44 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
Study: NCT00933023
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1%hydrocortisone topical once daily for 8 weeks
Study: NCT04380935
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to national or hospital guidelines COVID-19 Management Protocol
Study: NCT01173523
Drug: STA-9090
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00151879
Drug: SPM 927
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03390608
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
Study: NCT03390608
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy versus no chemotherapy.
Study: NCT02029118
Drug: Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)
Normalized name: Trichosanthes kirilowii fruit rind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
Study: NCT00920868
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 850 mg/m2 PO BID on days 1-14
Study: NCT00469430
Drug: cefotaxim and metronidazol
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv administration for at least 24 h
Study: NCT00707239
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
Study: NCT00707239
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
Study: NCT02129231
Drug: Ezetimibe/simvastatin
Normalized name: EZETIMIBE/SIMVASTATIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: We ensured the patient took the drug at night before meals
Study: NCT02129231
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: We ensured the patient took the drug at night before meals
Study: NCT00063934
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00843050
Drug: P276-00
Approvals — FDA: no, EMA: no, PMDA: no
Description: P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
Study: NCT02234141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT04285853
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets.
Study: NCT00877604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo by oral route at the same dosing schedule
Study: NCT00003852
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02257346
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
Study: NCT02125682
Drug: atovastatin 10 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks
Study: NCT02556320
Drug: anti-epileptic drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
Study: NCT00707148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
Study: NCT03017404
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02093169
Drug: Part A: Lu AF35700
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 30 mg single dose for one day; orally
Study: NCT00712712
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of paracetamol (4 g / 24h) and patient-controlled analgesia (PCA).
Study: NCT01772810
Drug: Human spinal cord stem cells.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
Study: NCT02044302
Drug: Analgesics
Normalized name: ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02093169
Drug: Part B: Lu AF35700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
Study: NCT02630966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride IV infusion
Study: NCT04029584
Drug: Fluvastatin 20 MG
Normalized name: fluvastatin 20 MG
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one oral dose of fluvastatin (Lescol ) 20mg capsule
Study: NCT00038402
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 by vein on Days 1 and 4 for 4 cycles at 3-4 week intervals.
Study: NCT04537078
Drug: Cetrotide Injectable Product
Normalized name: Cetrotide Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: will used in the second arm for pituitary suppression in the second group daily when the biggest oocyte reaches size 14 mm till ovulation triggering
Study: NCT02570308
Drug: IMCgp100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3
Study: NCT01960413
Drug: Montelukast added to Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01960413
Drug: Placebo added to Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00357292
Drug: Azithromycin (T1225)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01109212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
Study: NCT01750775
Drug: placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
Study: NCT03266146
Drug: 36 Weeks Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 36 weeks. Follow-up duration is 24 weeks.
Study: NCT03266146
Drug: 48 weeks Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
Study: NCT01116271
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 or 75mg, capsules, PO, BID, 28 days
Study: NCT03691519
Drug: Omega-3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient in the treatment comparative arm will consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day).
Study: NCT00144820
Drug: Injection of Hyaluronan or Saline
Normalized name: Rosula NS Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03762265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT01805089
Drug: Melatonin 3 mg
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin vs. Placebo
Study: NCT02287181
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: short acting opiate
Study: NCT01153815
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02519374
Drug: PROMITOR® (including Maltodextrin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product dose 1
Study: NCT02519374
Drug: PROMITOR® (including Maltodextrin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product dose 2
Study: NCT02519374
Drug: PROMITOR® (including Maltodextrin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product dose 3
Study: NCT04389229
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg/m2/day for 3 days ( on day -5, -4, -3)
Study: NCT02245516
Drug: KPI-121 0.25% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Study: NCT02245516
Drug: KPI-121 1.0% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.